Long-term Safety of BCX9930 in Subjects With Paroxysmal Nocturnal Hemoglobinuria
Status:
Recruiting
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
This study is designed to provide continued access to BCX9930 for subjects currently
receiving treatment with BCX9930 in a BioCryst-sponsored clinical study for paroxysmal
nocturnal hemoglobinuria (PNH) who, in the opinion of the investigator, would benefit from
continued treatment with BCX9930 and who do not have access to other treatment options.